Publications
Detailed Information
Long-term angiogenesis efficacy using a heparin-conjugated fibrin (HCF) delivery system with HBM-MSCs
Cited 0 time in
Web of Science
Cited 1 time in Scopus
- Authors
- Issue Date
- 2012-05
- Publisher
- Korean Society for Stem Cell Research
- Citation
- International Journal of Stem Cells, Vol.5 No.1, pp.23-30
- Abstract
- Background and Objectives: Heparin-conjugated fibrin (HCF) is suitable for the release and localization of bFGF. We analyzed the effects of a bFGF delivery system using HCF with human bone marrow-derived mesenchymal stem cells (HBM- MSCs) in a dog ischemic limb model. Methods and Results: Animals were divided into HBM-MSCs, HBM-MSCs+HCF, bFGF-HCF, and HBM-MSCs+ bFGF-HCF groups. A total of 1×107 HBM-MSCs were injected per animal, and the amount of bFGF was 1 mg per dog. Ischemic muscles were harvested at eight weeks and six months after injection of cells. The HBM-MSCs+ bFGF-HCF group exhibited decreased proportions of capillaries and arterioles six months after transplantation. However, there were more cells positive for the angiogenic factors, VEGF and PDGF, in the eight-week specimens compared with those harvested six months after transplantation. Conclusions: Our results demonstrated that a single injection of HBM-MSCs did not have significant long-term angiogenic effects; however, a bFGF delivery system using HCF exerted prolonged angiogenic effects when combined with HBM-MSCs.
- ISSN
- 2005-3606
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.